Back

Ingenia expands TIE2 drug platform into kidney disease with U.S. trial

Verifying
  • Ingenia filed a U.S. application to test IGT-303 in chronic kidney disease.
  • The planned Phase 1/2a trial will enroll 94 participants across five U.S. sites.
  • MSD began global Phase 3 testing of MK-8748 after acquiring EyeBio.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.